3 articles
At least nine significant funding rounds in Q1 2026 brought total BCI investment past $960 million, with capital spreading across invasive, endovascular, ultrasound, and neurostimulation modalities.
Science Corporation closes a $230 million Series C led by Khosla Ventures and Lightspeed, pushing its valuation past $1 billion as it targets European launch of the PRIMA vision-restoration implant by mid-2026.
A new partnership between Science Corp and Neurosoft AI aims to dramatically reduce the cost and timeline of brain-computer interface clinical trials through shared infrastructure and software tools.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.